Progress in Shark Single-Area Antibody

Monoclonal antibody (mAb) is a vital organic macromolecule and broadly utilized in immune detection, in vitro diagnostics, and drug discovery. Nevertheless, the inherent properties of mAb prohibit its additional growth, akin to excessive molecular weight and complicated construction. Subsequently, there’s an pressing have to develop options for mAb. Varied kinds of miniaturized antibodies have been developed, amongst which the variable area of immunoglobulin new antigen receptor (VNAR) could be very engaging.

 

Genatur Prices
Genatur Prices

 

Recombinant Metarhizium robertsii Probable Xaa-Pro aminopeptidase MAA_08947 (MAA_08947)

MBS1217960-01mgEColi 0.1mg(E-Coli)
EUR 1235

Recombinant Metarhizium robertsii Probable Xaa-Pro aminopeptidase MAA_08947 (MAA_08947)

MBS1217960-01mgYeast 0.1mg(Yeast)
EUR 1315

Recombinant Metarhizium robertsii Probable zinc metalloprotease MAA_05014 (MAA_05014), partial

MBS1012216-1mgEColi 1mg(E-Coli)
EUR 1575

Recombinant Metarhizium robertsii Probable zinc metalloprotease MAA_05014 (MAA_05014), partial

MBS1012216-1mgYeast 1mg(Yeast)
EUR 2080

Melanoma Associated Antigen (MAA)(MAA/1414), 0.2mg/mL

BNUB1414-100 1uL
EUR 225
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Melanoma Associated Antigen (MAA)(MAA/1414), 0.2mg/mL

BNUB1414-500 1uL
EUR 485
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Melanoma Associated Antigen (MAA)(MAA/1414), 1mg/mL

BNUM1414-50 1uL
EUR 396
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Melanoma Associated Antigen (MAA)(MAA/1414), CF594 conjugate, 0.1mg/mL

BNC941414-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Melanoma Associated Antigen (MAA)(MAA/1414), CF594 conjugate, 0.1mg/mL

BNC941414-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Melanoma Associated Antigen (MAA)(MAA/1414), CF647 conjugate, 0.1mg/mL

BNC471414-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Melanoma Associated Antigen (MAA)(MAA/1414), CF647 conjugate, 0.1mg/mL

BNC471414-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Melanoma Associated Antigen (MAA)(MAA/1414), CF568 conjugate, 0.1mg/mL

BNC681414-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Melanoma Associated Antigen (MAA)(MAA/1414), CF568 conjugate, 0.1mg/mL

BNC681414-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Melanoma Associated Antigen (MAA)(MAA/1414), CF405S conjugate, 0.1mg/mL

BNC041414-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Melanoma Associated Antigen (MAA)(MAA/1414), CF405S conjugate, 0.1mg/mL

BNC041414-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Melanoma Associated Antigen (MAA)(MAA/1414), CF488A conjugate, 0.1mg/mL

BNC881414-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Melanoma Associated Antigen (MAA)(MAA/1414), CF488A conjugate, 0.1mg/mL

BNC881414-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Melanoma Associated Antigen (MAA)(MAA/1414), CF640R conjugate, 0.1mg/mL

BNC401414-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Melanoma Associated Antigen (MAA)(MAA/1414), CF640R conjugate, 0.1mg/mL

BNC401414-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Melanoma Associated Antigen (MAA)(MAA/1414), Biotin conjugate, 0.1mg/mL

BNCB1414-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Melanoma Associated Antigen (MAA)(MAA/1414), Biotin conjugate, 0.1mg/mL

BNCB1414-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

MA1A2 rabbit pAb

E28PN5168 100μl
EUR 255
Description: Available in various conjugation types.

MA1A2 rabbit pAb

E44H14052 100ul
EUR 255
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

MA1A2 Antibody

C42283-100ul 100μl
EUR 217
Description: MA1A2 Rabbit Polyclonal Antibody

MA1A2 Antibody

C42283-50ul 50μl
EUR 143.5
Description: MA1A2 Rabbit Polyclonal Antibody

MA1A2 Rabbit Polyclonal Antibody

BT-AP11203-100ul 100ul Ask for price

MA1A2 Rabbit Polyclonal Antibody

BT-AP11203-20ul 20ul Ask for price

MA1A2 Rabbit Polyclonal Antibody

BT-AP11203-50ul 50ul Ask for price

Plant Melanoma Associated Antigen 1 (MAA1) ELISA Kit

MBS9378260-INQUIRE INQUIRE Ask for price

(±)-Maackiain; dl- Maackiain

N1956-20 20 mg
EUR 200
Description: Extracted from Gao Lihuai;Store the product in sealed,cool and dry condition

Plant Melanoma-Associated Antigen 4 (MAA4) ELISA Kit

MBS9378047-INQUIRE INQUIRE Ask for price

Bovine Melanoma-Associated Antigen 4 (MAA4) ELISA Kit

MBS9373006-10x96StripWells 10x96-Strip-Wells
EUR 6725

Bovine Melanoma-Associated Antigen 4 (MAA4) ELISA Kit

MBS9373006-48StripWells 48-Strip-Wells
EUR 550

Bovine Melanoma-Associated Antigen 4 (MAA4) ELISA Kit

MBS9373006-5x96StripWells 5x96-Strip-Wells
EUR 3420

Bovine Melanoma-Associated Antigen 4 (MAA4) ELISA Kit

MBS9373006-96StripWells 96-Strip-Wells
EUR 765

Maackia amurensis (MAA) (Texas Red)

MBS655945-1mg 1mg
EUR 460

Maackia amurensis (MAA) (Texas Red)

MBS655945-5x1mg 5x1mg
EUR 1910

Maackia amurensis Lectin (MAA/MAL I) - Cy3

21761120-1 1 mg
EUR 134.51

Maackia amurensis Lectin (MAA/MAL I) - Cy5

21761121-1 1 mg
EUR 134.51

Maackia amurensis Lectin (MAA/MAL II) - Cy3

21511109-1 1 mg
EUR 145.5

Maackia amurensis Lectin (MAA/MAL II) - Cy5

21511110-1 1 mg
EUR 145.5

Maackia amurensis Lectin (MAA/MAL I+II) - Cy3

21511122-1 1 mg
EUR 136.34

Maackia amurensis Lectin (MAA/MAL I+II) - Cy5

21511123-1 1 mg
EUR 136.34

Maackia amurensis Lectin (MAA/MAL I) - Pure

21510007-1 1 mg
EUR 85.98

Maackia amurensis Lectin (MAA/MAL I) - Pure

21510007-2 5 mg
EUR 147.3
  • The shark single-domain antibody, often known as shark VNAR, is an antigen-binding area obtained by genetic engineering expertise based mostly on the immunoglobulin new antigen receptor (IgNAR) that naturally exists in selachimorpha.

 

  • It has a molecular weight of 12 kDa, which is the smallest antigen-binding area discovered within the identified vertebrates at current. In contrast with mAb, the shark VNAR displays numerous superiorities, akin to low molecular weight, excessive affinity, tolerance to the cruel setting, good water solubility, robust tissue penetration, and recognition of the hidden epitopes.

 

It has attracted large consideration within the fields of immunochemical reagents and drug discovery. On this evaluation, numerous points of shark VNAR are elaborated, together with the structural and purposeful traits, producing and humanization strategies, affinity maturation methods, utility fields, benefits and drawbacks, and prospects.

 

Islet, thyroid and transglutaminase antibodies in grownup Bulgarian sufferers with kind 1 diabetes

 

Goal: The goal of the examine was to evaluate the prevalence and relationship of islet antibodies and autoantibodies of the commonest related autoimmune diseases-autoimmune thyroid illness (AITD) and celiac illness, in grownup Bulgarian sufferers with kind 1 diabetes of brief period.
Materials and strategies: 160 kind 1 diabetes sufferers, of imply age 36.3 ± 10.9 years, imply BMI 23.0 ± 4.2 kg/m2 and imply illness period 1.35 ± 1.69 years have been enrolled. Pancreatic islet cell antibodies-glutamic acid decarboxylase antibodies (GAD 65-Ab), tyrosine phosphatase antibodies (IA 2-Ab), and zinc transporter Eight antibodies (ZnT8-Ab), thyroid antibodies-thyroperoxidase and thyroglobulin antibodies, and transglutaminase antibodies (TTG-IgA-Ab) have been assessed by ELISA.
Outcomes: 87.5% of the sufferers had a number of of the islet antibodies-78.1% had GAD 65-Ab, 53.1%-ZnT8-Ab, and 34.4%-IA 2-Ab. 5% introduced as simply ZnT8-Ab constructive. GAD 65-Ab recognized 90.6% of the antibody constructive sufferers. The addition of IA 2-Ab as a second immunologic marker recognized 94.4%, whereas the usage of ZnT8-Ab in second place recognized 98.8% of the instances. 24.4% introduced with constructive thyroid antibodies and 33.8% had AITD. No relation was discovered between any of the islet antibodies and AITD. Not one of the sufferers was TTG-IgA-Ab constructive. No vital correlations have been established between the antibodies with completely different organ specificity.
Conclusions: In grownup Bulgarian kind 1 diabetes sufferers ZnT8-Ab is an impartial diagnostic marker ranking second in prevalence and diagnostic significance after GAD 65-Ab. AITD impacts about one third of this inhabitants and routine screening is required, whereas screening for celiac illness shouldn’t be justified.
Key phrases: Autoimmune thyroid illness; Autoimmunity; Celiac illness; Islet antibodies; Sort 1 diabetes.

Eph Receptors as Most cancers Targets for Antibody-based Remedy

Receptor tyrosine kinases (RTKs) are integral membrane sensors that govern cell differentiation, proliferation and mobility, and allow fast communication between cells and their setting. Of the 20 RTK subfamilies at present identified, Eph receptors are the most important group.

Macranthoside B

HY-N5008 10mg
EUR 846

Macranthoidin B

N2410-20 20 mg
EUR 280
Description: Bioactive saponin

Macranthoidin B

T3367-10mg 10mg Ask for price
Description: Macranthoidin B

Macranthoidin B

T3367-1g 1g Ask for price
Description: Macranthoidin B

Macranthoidin B

T3367-1mg 1mg Ask for price
Description: Macranthoidin B

Macranthoidin B

T3367-50mg 50mg Ask for price
Description: Macranthoidin B

Macranthoidin B

T3367-5mg 5mg Ask for price
Description: Macranthoidin B

Macranthoside B

T5787-10mg 10mg Ask for price
Description: Macranthoside B

Macranthoside B

T5787-1g 1g Ask for price
Description: Macranthoside B

Macranthoside B

T5787-1mg 1mg Ask for price
Description: Macranthoside B

Macranthoside B

T5787-50mg 50mg Ask for price
Description: Macranthoside B

Macranthoside B

T5787-5mg 5mg Ask for price
Description: Macranthoside B

Macranthoidin B

TB0339-1000 20mg
EUR 243.6

Macranthoidin A

TB0460-0020 25mg
EUR 298.8

Macranthoside A

TN1831-10mg 10mg Ask for price
Description: Macranthoside A

Macranthoside A

TN1831-1g 1g Ask for price
Description: Macranthoside A

Macranthoside A

TN1831-1mg 1mg Ask for price
Description: Macranthoside A

Macranthoside A

TN1831-50mg 50mg Ask for price
Description: Macranthoside A

Macranthoside A

TN1831-5mg 5mg Ask for price
Description: Macranthoside A

macranthoidin A

T3858-10mg 10mg Ask for price
Description: macranthoidin A

macranthoidin A

T3858-1g 1g Ask for price
Description: macranthoidin A

macranthoidin A

T3858-1mg 1mg Ask for price
Description: macranthoidin A

macranthoidin A

T3858-50mg 50mg Ask for price
Description: macranthoidin A

macranthoidin A

T3858-5mg 5mg Ask for price
Description: macranthoidin A

macranthoidin A

MBS579808-10mg 10mg
EUR 220

macranthoidin A

MBS579808-25mg 25mg
EUR 310

macranthoidin A

MBS579808-2mg 2mg
EUR 155

macranthoidin A

MBS579808-50mg 50mg
EUR 420

macranthoidin A

MBS579808-5mg 5mg
EUR 175

Macranthoidin B

MBS578401-10mg 10mg
EUR 200

Macranthoidin B

MBS578401-25mg 25mg
EUR 265

Macranthoidin B

MBS578401-2mg 2mg
EUR 145

Macranthoidin B

MBS578401-50mg 50mg
EUR 385

Macranthoidin B

MBS578401-5mg 5mg
EUR 160

Macranthoidin B

MBS3840571-10mg 10mg
EUR 275

Macranthoidin B

MBS3840571-25mg 25mg
EUR 480

Macranthoidin B

MBS3840571-5mg 5mg
EUR 195

Macranthoidin B

MBS3840571-5x25mg 5x25mg
EUR 2160

Macranthoidin B

MBS3607255-10mg 10mg
EUR 315

Macranthoidin B

MBS3607255-25mg 25mg
EUR 480

Macranthoidin B

MBS3607255-2mg 2mg
EUR 220

Macranthoidin B

MBS3607255-50mg 50mg
EUR 670

Macranthoidin B

MBS3607255-5mg 5mg
EUR 255

macranthoidin A

MBS3607994-5mg 5mg
EUR 230

macranthoidin A

MBS3607994-5x5mg 5x5mg
EUR 710

Macranthoside B

MBS3610385-5mg 5mg
EUR 375

Macranthoside B

MBS3610385-5x5mg 5x5mg
EUR 1355

Macranthoside B

MBS5752136-10mg 10mg
EUR 525

Macranthoside B

MBS5752136-1mg 1mg
EUR 215

Macranthoside B

MBS5752136-25mg 25mg
EUR 800

Macranthoside B

MBS5752136-2mg 2mg
EUR 260

Macranthoside B

MBS5752136-5mg 5mg
EUR 325

Recombinant Hoplocorypha cf. macra Periviscerokinin-2

MBS1171879-005mgBaculovirus 0.05mg(Baculovirus)
EUR 875

Recombinant Hoplocorypha cf. macra Periviscerokinin-2

MBS1171879-005mgEColi 0.05mg(E-Coli)
EUR 490

Recombinant Hoplocorypha cf. macra Periviscerokinin-2

MBS1171879-005mgYeast 0.05mg(Yeast)
EUR 690
  • Along with their corresponding ephrin ligands, Eph receptors regulate a various array of physiologic processes together with axonal steerage, bone transforming, and immune cell growth and trafficking.

 

  • Deregulation of Eph signaling pathways is linked to most cancers and different proliferative ailments and, as a result of RTKs play crucial roles in most cancers growth, the particular concentrating on of those molecules in malignancies offers a promising therapy strategy.

 

  • Monoclonal antibodies concentrating on RTKs symbolize a doubtlessly engaging modality for pharmaceutical growth attributable to their comparatively excessive goal specificity and low off-target binding charges.

 

Subsequently, new applied sciences to generate antibodies capable of goal RTKs of their native in vivo context are more likely to facilitate pre-clinical and medical growth of antibody-based therapies. Our group has lately reported a platform discovery methodology termed Choice of Phage-displayed Accessible Recombinant Focused Antibodies (SPARTA).

 

SPARTA is a novel and sturdy stepwise methodology, which mixes the attributes of in vitro screenings of a naïve human recombinant antibody library in opposition to identified tumor targets with these options of in vivo picks based mostly on tumor-homing capabilities of a pre-enriched antibody pool. This distinctive strategy overcomes a number of rate-limiting challenges to generate human monoclonal antibodies amenable to fast translation into medical purposes.